All Drug Discovery articles
-
NewsResearchers solve 30-year mystery of key inflammatory enzyme gene
A gene responsible for producing a critical enzyme in inflammatory signalling has been identified after more than 30 years, with findings suggesting the pathway acts as both an immune alarm and a cellular shield with implications for cancer, IBD and asthma.
-
NewsSelf-driving labs and advanced cell models feature at ELRIG 2026
From self-driving laboratories to advanced cellular models, ELRIG Drug Discovery 2026 showcases technologies helping researchers generate better data, evaluate drug candidates and improve early discovery.
-
NewsBCAT1 enzyme identified as fibrosis target after heart attack
Researchers at Nagoya University have identified BCAT1, an enzyme involved in proline supply for collagen synthesis, as a potential target for reducing cardiac fibrosis following myocardial infarction.
-
Newsbit.bio launches refined human astrocyte model for neurotoxicity assessment
Cambridge biotech bit.bio has released ioAstrocytes 2.0, a genetically matched human astrocyte model designed to support functional neuroscience research and earlier assessment of seizure liability and neurotoxicity in drug development.
-
NewsPacBio and TychoBio partner to advance AI-driven RNA therapies
PacBio and AI drug discovery company TychoBio are generating full-length RNA datasets from more than 10,000 samples to train AI models and accelerate the development of RNA therapies for rare diseases.
-
ArticleFinding drug targets through the noise of complex disease
The strongest disease signal may not point to the best drug target. AI could help researchers identify what matters within complex biological networks.
-
NewsSpeakers announced for Protein Sciences in Drug Discovery 2026 in Stevenage
Three leading scientists in protein science, structural biology and AI will headline the Protein Sciences in Drug Discovery conference at GSK Stevenage in November 2026, exploring advances in AI-driven drug design, native mass spectrometry and membrane protein folding.
-
NewsTazbentetol shows retinal neuroprotection potential in diabetic mouse model
Experimental synaptic restoration compound tazbentetol has demonstrated neuroprotective effects in the retinas of diabetic mice, offering a potential new therapeutic avenue for diabetic retinal neuropathy ahead of detectable vascular damage.
-
NewsVPS34 inhibition boosts GD2 visibility to enhance neuroblastoma immunotherapy
Penn State researchers have shown that inhibiting the protein VPS34 increases GD2 display on neuroblastoma cell surfaces, making tumours more visible to anti-GD2 antibodies and improving outcomes in preclinical combination studies.
-
NewsCMA restoration may clear senescent cells in ageing tissues
Researchers at Albert Einstein College of Medicine have identified a cellular recycling pathway whose age-related decline allows senescent ‘zombie’ cells to evade immune clearance.
-
NewsELRIG Drug Discovery 2026 celebrates 20th anniversary at ExCeL London
ELRIG Drug Discovery 2026 returns to ExCeL London for its 20th year, with AI, automation and advanced cell models among the technologies set to feature across the two-day programme.
-
NewsSynthetic protein targets TLR4 within membrane to curb inflammation
Scientists at Scripps Research have engineered a synthetic protein capable of binding to Toll-like receptor 4 within the cell membrane, reducing inflammatory signalling.
-
InterviewA sceptical guide to AI agents in drug discovery
AI agents promise to transform drug discovery, but where do they really add value? Dr Eric Ma examines search, model choice, vendor lock-in and why scientific expertise matters more than ever.
-
NewsInsilico Medicine nominates AI-designed ISM1354 GIPR antagonist for obesity
Insilico Medicine has nominated ISM1354, an AI-designed small-molecule GIPR antagonist, as a preclinical candidate for obesity and related metabolic disorders.
-
ArticleDrug discovery in Q3 2026 – what changed and why it matters
Agentic AI, ultralarge virtual screening, molecular glues and human-relevant models were among the key developments in early drug discovery during Q3 2026. Drug Target Review examines what changed, why it matters and what to watch heading into Q4.
-
NewsAI consortium targets antibody developability prediction with 10,000-sequence dataset
A new industry consortium led by Ginkgo Datapoints and Apheris is assembling a 10,000-antibody dataset to train AI models that can flag developability problems earlier in the drug discovery pipeline.
-
ArticleInduced proximity drugs – why complex formation is not enough
A drug can form exactly the complex it was designed to make and still fail to work. Two recently approved induced proximity drugs show why what happens after complex formation – not formation alone – can decide the outcome.
-
NewsNew P. vivax vulnerability could prevent liver-stage malaria infection
A newly identified epitope on the circumsporozoite protein of Plasmodium vivax could offer a route to vaccines that prevent liver-stage infection and curb the relapse-driven transmission cycle.
-
NewsMenin inhibitor KO-7246 shows β-cell regeneration in preclinical diabetes models
New preclinical data suggests that menin inhibitor KO-7246 can regenerate functional pancreatic β-cells and sustain improvements in blood glucose control across both Type 1 and Type 2 diabetes models.
-
NewsBrain circuit linking cold exposure to metabolism identified in hypothalamus
Researchers at USF Health have identified a previously unknown brain circuit in the hypothalamus that coordinates eating behaviour, heat production and energy expenditure in response to cold, with implications for obesity and metabolic disease drug discovery.